

Get CardioSmart!!



By
Sheree Schroeder, MSN, RN, RDCS,
FASE
Indiana CCA Liaison
Director of Quality Review Services
Accreditation for Cardiovascular
Excellence



OK Full Disclosure ©

CardioSmart is the ACC patient education and empowerment initiative brought to you by the American College of Cardiology. Our mission is to help individuals prevent, treat and manage cardiovascular disease. You will learn more about ACC CardioSmart product from our next speaker. I am going to discuss with you today how you can stay "cardio smart".



OK Where do we as CV Team Members Find Reliable Information?



- ACC- Is Your Professional Organization
 - Cardiosource.org
 - CardioSmart.org
- Attend State and National Scientific Meetings
- ACCN
- ANA
- Medscape.com
 - "Ending Opioid Abuse-What Clinicians Can Do"
- MedPage Today-Medpagetoday.com



So What's the Buzz in Cardiology?



Niacin PCSK-9

Treatment Goals for Lipids?

Stem Cells

TVAR

TCT-Renal Artery Denervation Still Alive

Radials

Femoral Closure Devices

Accreditations for CCls

Team Based Approach Best with Everything



Niacin



Niacin treatment did not reduce the primary end point across tertiles of any baseline lipid parameters.



PCSK-9



AMG-145 is a fully human monoclonal antibody toPCSK-9, the natural inhibitor of the LDL receptor. The drug lowers LDL-C and maximizes the potential benefit of statins. Clinical trials are ongoing with at least two PCSK-9 inhibitors, including one that is a clinical outcome study. While requiring an injection biweekly or monthly, the absence of side effects and adverse events in the early studies makes this a very attractive lipid-lowering drug for resistant hypercholesterolemia, and has the potential to reduce the 'residual risk' in coronary heart disease patients on maximal doses of statins.



PCSK-9



In phase 1 studies, (18 months ago)AMG 145 significantly reduced serum LDL-C in healthy and hypercholesterolemic statin-treated subjects, including those with heterozygous familial hypercholesterolemia or taking the highest doses of atorvastatin or rosuvastatin, with an overall AE profile similar to placebo.



Now



Phase III- Odyssey Mono-July 2014


- 1 cc injection 75 mg every two weeks
 - 47-54% reduction

LDL below 70 is non atherogenic

http://biomarkers.cardiosource.org/Video-News/Video/2014-July-First-Phase-3-Data-Being-Reported-for-a-PCSK9-Inhibitors.aspx



Lipid Targets?



There is no evidence to support continued use of specific LDL-C and/or non-high-density lipoprotein cholesterol (non-HDL-C) treatment targets. The appropriate intensity of statin therapy should be used to reduce risk in those most likely to benefit.





Stem Cell Research at Stanford
Capabilities to Re-assign Stem
Cells

Pluripotent Stem Cells-Embronic
Induced PSC-(IPSC) 2 wks
Genome Editing of Isogenic IPSCs

Joewu@stanford.edu



TAVR



It is Here to Stay!

High Value- 50 K

(Medical Therapy does not work for AS)

New Valves



Radials



Here to Stay

Cost Effective
Safer
Patient Satisfier



TCT 2014 Wrap-up!

Renal Artery Denervation Lives

Partner I Trial-5 year follow-up ©

1 year vs 2.5 year survival

Asorb II

Femoral Artery Closure

Vs

Manual Pressure







(CAS)





(CC)

Percutaneous Coronary Intervention (PCI)



Peripheral Vascular Disease (PVD)



What's New with ACE?



DX and PCI

Carotids

CHD

PVD

TAVR

EP





Patient Care
Mitigating Financial Risk
Documentation
Patient Education
Lobbying



In Summary-Be Exceptional Be CardioSmart



Education- Life Long Learning
Professional Societies- Stay Connected

Mentoring

Networking

Attitude

Make a Difference!



References:



http://www.cardiosource.org



Questions ??



How can ACC better serve you?